CPMD — Cannapharmarx Share Price
Last trade - 00:00- $2.92m
- $11.35m
- $0.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -523.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.82 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CannaPharmaRX Inc. is a Canada-based cannabis company focused on producing customizable medical cannabis and craft products. The Company operates from its facility in Cremona, AB, Canada, and is able to produce over 6,000 kgs per year. The Company is focused on evaluation, negotiation, acquisition, and development cannabis cultivation projects in Canada. The Company's products include unique genetics, craft products, medical cannabis, its brands and licenses. In addition to medical cannabis, it has also created some craft products. Craft cannabis, also known as craft marijuana, is cannabis that is produced on a small scale by artisanal or independent producers.
Directors
- Dominick Colvin CHM (54)
- James Samuelson CEO (50)
- John Cassels CFO (72)
- Andrew Steedman EVP (58)
- Marc Branson DRC (45)
- Richard Orman DRC (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 2010
- Public Since
- October 29th, 1999
- No. of Shareholders
- 320
- No. of Employees
- 26
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 662,956,405
- Address
- Suite 3600, 888 3rd Street Sw, CALGARY, T2P 5C5
- Web
- https://www.cannapharmarx.com
- Phone
- +1 9496526838
- Auditors
- Barzily & Co.
Upcoming Events for CPMD
Similar to CPMD
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:46 UTC, shares in Cannapharmarx are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Cannapharmarx last closed at $0.00 and the price had moved by -56% over the past 365 days. In terms of relative price strength the Cannapharmarx share price has underperformed the S&P500 Index by -58.89% over the past year.
There is no consensus recommendation for this security.
Find out moreCannapharmarx does not currently pay a dividend.
Cannapharmarx does not currently pay a dividend.
Cannapharmarx does not currently pay a dividend.
To buy shares in Cannapharmarx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Cannapharmarx had a market capitalisation of $2.92m.
Here are the trading details for Cannapharmarx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CPMD
Based on an overall assessment of its quality, value and momentum Cannapharmarx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cannapharmarx. Over the past six months, its share price has underperformed the S&P500 Index by -53.52%.
As of the last closing price of $0.00, shares in Cannapharmarx were trading -51.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cannapharmarx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cannapharmarx's management team is headed by:
- Dominick Colvin - CHM
- James Samuelson - CEO
- John Cassels - CFO
- Andrew Steedman - EVP
- Marc Branson - DRC
- Richard Orman - DRC